{
    "2021-03-29": [
        [
            {
                "time": "2023-03-15",
                "original_text": "中国银河给予贝达药业推荐评级，埃克替尼继续快速放量，恩沙替尼获批打破单药困局",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "推荐评级",
                        "埃克替尼",
                        "恩沙替尼",
                        "获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-16",
                "original_text": "医药行业周报：本周医药涨幅居前 建议关注核心资产触底反弹",
                "features": {
                    "keywords": [
                        "医药行业",
                        "涨幅",
                        "核心资产",
                        "触底反弹"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-17",
                "original_text": "华鑫证券维持贝达药业推荐评级：业绩符合预期，多个产品进入收获期",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "推荐评级",
                        "业绩",
                        "收获期"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-18",
                "original_text": "西部证券维持贝达药业买入评级：埃克替尼持续放量，研发管线迎来收获期",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "买入评级",
                        "埃克替尼",
                        "研发管线",
                        "收获期"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-19",
                "original_text": "贝达药业盈利狂飙背后：研发投入占比惊人维持在40%左右",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "盈利",
                        "研发投入",
                        "40%"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-20",
                "original_text": "卡瑞利珠单抗2项新适应证报上市；艾力斯艾弗沙患者援助项目启动；贝达药业、赛生药业、先声药业2020年业绩报告",
                "features": {
                    "keywords": [
                        "卡瑞利珠单抗",
                        "适应证",
                        "艾力斯",
                        "艾弗沙",
                        "贝达药业",
                        "赛生药业",
                        "先声药业",
                        "业绩报告"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-21",
                "original_text": "华西证券维持贝达药业买入评级：业绩符合预期，后期管线快速推进",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "买入评级",
                        "业绩",
                        "后期管线",
                        "快速推进"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}